A blockchain genomics pioneer has joined forces with a Nasdaq-Listed molecular diagnostics company to accelerate cancer detection through a “critical mass” of genomics data.
Blockchain-powered database platform
Shivom announced Tuesday that it has entered into a partnership with molecular diagnostics company
Genetic Technologies Ltd. (NASDAQ: GENE) to accelerate the prediction of cancer in millions of patients worldwide.
Genetic Technologies’ lead product is
BREVAGenplus, a risk assessment test for non-hereditary breast cancer. Though assembling the data to develop the tests has taken nearly a decade, rhrough Shivom, it is expected the timelines will be massively reduced. Shivom has created a secure global genomic ecosystem that aims to become the largest healthcare data-hub on the planet.
Co-founder & CEO of Shivom Axel Schumacher stated in a news release -
"By bringing together the millions of individuals' genomic profiles that Shivom enables, with [Genetic Technologies’] market leading tests, we will create critical mass that accelerates transformative disease prevention and personalized healthcare."